Symbols

MGX

Metagenomi·NASDAQ

--(--)

MGX Profile

Metagenomi Therapeutics, Inc.

A precision gene editing biotechnology company

Industry

Biological Technology

Established Date

Listing Date

02/09/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

119

Fiscal Year Ends

12-31

Website

www.metagenomi.co

Security Type

Common stock

Office address

5959 Horton Street, 7th Floor, Emeryville, California 94608

Business

Introduction

Metagenomi Therapeutics, Inc., was originally formed in September 2016 and started its existing business as a Delaware limited liability company in 2018. The company is an in vivo gene editing company focused on the development of curative gene medicines using proprietary gene editing tools derived from metagenomics. Its wholly-owned lead project, MGX-001, aims to treat hemophilia A and continues to advance its R&D pipeline for genetic diseases through a variety of editing methods.